|
Peter K. Honig is Director-Drug Safety at Center for Drug Evaluation & Research and on the board of 7 other companies.
Dr. Honig previously occupied the position of Member-Management Board at Medical Dictionary For Regulatory Activities, Senior VP-Worldwide Regulatory Affairs & Product S at Merck & Co., Inc., Senior VP & Head-Global Regulatory Affairs at Pfizer Inc., Director-Drug Safety at US Food & Drug Administration, Head-Global Regulatory Affairs & Patient Safety at AstraZeneca LP and President of The American Society for Clinical Pharmacology & Therapeutics.
He received a doctorate from Columbia University College of Physicians & Surgeons, a graduate degree from Joseph L. Mailman School of Public Health, an undergraduate degree from Columbia College (New York) and a graduate degree from The Trustees of Columbia University in The City of New York.
|
Posiciones actuales de Peter K. Honig | |
|
Nombre | Puesto |
Desde |
Karyopharm Therapeutics Inc. (Biotecnología e investigación médica) |
Independent Director |
2021 | Sesen Bio, Inc. (Biotecnología e investigación médica) |
Independent Director |
2021 | Alopexx, Inc. (Biotecnología e investigación médica) |
Independent Director |
- | Drug Information Association |
Director |
2021 | Alopexx Enterprises LLC |
Director |
- | Accelerating Therapeutics for Opportunities in Medicine |
Director |
- | Aerium Therapeutics, Inc. |
Director |
- | Center for Drug Evaluation & Research |
Director-Drug Safety |
- |
|
Participaciones de Peter K. Honig | |
|
Nombre | Acciones | % | Valoración |
Sesen Bio, Inc. (SESN) (Biotecnología e investigación médica) | 40 000 | 0,020% | 24 360 USD |
|
Peter K. Honig: Red personal | |
|
|
© 2023 People and Ownership :
|
Peter K. Honig Conexiones | |
|
|
|